Amicus Therapeutics (FOLD) Competitors

Alkermes (NASDAQ:ALKS) and Amicus Therapeutics (NASDAQ:FOLD) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Do analysts rate ALKS or FOLD?

Alkermes currently has a consensus target price of $35.38, suggesting a potential upside of 48.32%. Amicus Therapeutics has a consensus target price of $20.00, suggesting a potential upside of 88.50%. Given Alkermes' stronger consensus rating and higher possible upside, analysts clearly believe Amicus Therapeutics is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Amicus Therapeutics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community prefer ALKS or FOLD?

Alkermes received 173 more outperform votes than Amicus Therapeutics when rated by MarketBeat users. However, 73.46% of users gave Amicus Therapeutics an outperform vote while only 70.84% of users gave Alkermes an outperform vote.

Company	Underperform	Outperform
Alkermes	Outperform Votes 685 70.84%	Underperform Votes 282 29.16%
Amicus Therapeutics	Outperform Votes 512 73.46%	Underperform Votes 185 26.54%

Do institutionals and insiders believe in ALKS or FOLD?

95.2% of Alkermes shares are held by institutional investors. 4.8% of Alkermes shares are held by insiders. Comparatively, 2.1% of Amicus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Which has more risk and volatility, ALKS or FOLD?

Alkermes has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500.

Which has better valuation and earnings, ALKS or FOLD?

Alkermes has higher revenue and earnings than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.66B	2.43	$355.76M	$2.07	11.52
Amicus Therapeutics	$399.36M	7.85	-$151.58M	-$0.51	-20.80

Does the media favor ALKS or FOLD?

In the previous week, Alkermes had 14 more articles in the media than Amicus Therapeutics. MarketBeat recorded 15 mentions for Alkermes and 1 mentions for Amicus Therapeutics. Alkermes' average media sentiment score of 0.77 beat Amicus Therapeutics' score of 0.38 indicating that Amicus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	2 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amicus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is ALKS or FOLD more profitable?

Alkermes has a net margin of 21.39% compared to Alkermes' net margin of -37.96%. Amicus Therapeutics' return on equity of 16.10% beat Alkermes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	21.39%	16.10%	9.15%
Amicus Therapeutics	-37.96%	-119.46%	-20.40%

Summary

Alkermes beats Amicus Therapeutics on 12 of the 18 factors compared between the two stocks.